Literature DB >> 32665991

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.

Stefanie Schmidt1, Frank Kunath1,2, Bernadette Coles3, Desiree Louise Draeger1,4, Laura-Maria Krabbe1,5, Rick Dersch6, Samuel Kilian7, Katrin Jensen7, Philipp Dahm8,9, Joerg J Meerpohl10,11.   

Abstract

Entities:  

Keywords:  Administration, intravesical; BCG vaccine; Mitomycin; Systematic review; Urinary bladder neoplasms

Mesh：

Substances：

Year:  2020        PMID： 32665991      PMCID： PMC7329645          DOI： 10.4111/icu.2020.61.4.349

Source DB:  PubMed          Journal:  Investig Clin Urol        ISSN： 2466-0493


× No keyword cloud information.
  13 in total

1.  Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.

Authors:  W P Witjes; J A Witjes; G O Oosterhof; M J Debruyne
Journal:  Semin Urol Oncol       Date:  1996-02

2.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Authors:  A Böhle; D Jocham; P R Bock
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.

Authors:  Truls Gårdmark; Staffan Jahnson; Rolf Wahlquist; Hans Wijkström; Per-Uno Malmström
Journal:  BJU Int       Date:  2007-01-22       Impact factor: 5.588

4.  Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Authors:  D L Lamm; B A Blumenstein; E David Crawford; J D Crissman; B A Lowe; J A Smith; M F Sarosdy; P F Schellhammer; A I Sagalowsky; E M Messing; P Loehrer; H Barton Grossman
Journal:  Urol Oncol       Date:  1995 May-Jun       Impact factor: 3.498

5.  Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.

Authors:  J A Witjes; A P v d Meijden; L Collette; R Sylvester; F M Debruyne; A van Aubel; W P Witjes
Journal:  Urology       Date:  1998-09       Impact factor: 2.649

6.  Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.

Authors:  Martin G Friedrich; Uwe Pichlmeier; Hartwig Schwaibold; Stefan Conrad; Hartwig Huland
Journal:  Eur Urol       Date:  2007-03-12       Impact factor: 20.096

7.  A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.

Authors:  S Krege; G Giani; R Meyer; T Otto; H Rübben
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

8.  A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.

Authors:  Barbara Mangiarotti; Alberto Trinchieri; Alberto Del Nero; Emanuele Montanari
Journal:  Arch Ital Urol Androl       Date:  2008-12

Review 9.  Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

Authors:  M D Shelley; J B Court; H Kynaston; T J Wilt; B Coles; M Mason
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.

Authors:  Riikka Järvinen; Eero Kaasinen; Anna Sankila; Erkki Rintala
Journal:  Eur Urol       Date:  2009-04-16       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.